||AM095 is a potent LPA1 receptor antagonist with IC50 values of 0.98 and 0.73 μM for recombinant human or mouse LPA1 respectively.
||BMS-986020 is a selective antagonist of LPA1.
||Ki16425 is a competitive, potent and reversible antagonist to LPA1, LPA2 and LPA3 with Ki of 0.34 μM, 6.5 μM and 0.93 μM, respectively.
||AM966, a excellent affinity, specific, oral LPA1(IC50=17 nM) antagonist, suppresses LPA-stimulated intracellular calcium release.
||ONO-7300243 is an antagonist of lysophosphatidic acid receptor 1 (LPA1; IC50 : 0.16 μM).
||Tetradecyl phosphonate is a pan-antagonist of lysophosphatidic acid 1 (LPA1), LPA2, and LPA3 receptors.
||ASP6432 is an antagonist of type 1 lysophosphatidic acid receptor (LPA1). For human LPA1 and rat LPA1, the IC50s are 11 nM and 30 nM , respectively.
||AM095 free acid
||AM095 (free acid) is a potent LPA1 receptor antagonist (IC50s: 0.98 and 0.73 μM for recombinant human or mouse LPA1).
||Luzindole is a selective melatonin receptor antagonist. Luzindole inhibits experimental autoimmune encephalomyelitis and exerts antidepressant-like activity. Luzindole preferential
||LX-1031 is an effective and orally available inhibitor of tryptophan 5-hydroxylase (TPH). It also decreases serotonin (5-HT) synthesis peripherally.
||LPA2 antagonist 2
||LPA2 antagonist 2 is ＞480-fold more selective than LPA3 (IC50 of 13.85 μM).LPA2 antagonist 2 is a selective LPA2 antagonist with an IC50 of 28.3 nM and a Ki of 21.1 nM.
||1-Oleoyl lysophosphatidic acid sodium salt
||1-Oleoyl lysophosphatidic acid sodium salt is an Endogenous agonist of LPA1 and LPA2